AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04769011 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Neurophysiological evaluation
Description: Magnetic Resonance Imaging (structural MRI and DTI)
Study NCT04769011 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Genetic evaluation
Description: Either blood or saliva will be obtained for participants for DNA collection. DNA will be extracted in the Molecular Biology Laboratory at the Scientific Institute IRCCS Medea. Captured exome libraries will be sequenced using the Illumina NextSeq 500 in 100 bp paired end reads. Postsequencing reads will be aligned using BWA Enrichment application on BaseSpace. VCF file will be then marked using wANNOVAR (Wang Genomics Lab). The analysis will be focused on non-synonymous variants enrichment in Gene Ontology and Human Phenotype.
Study NCT01992783 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hi-maize resistant starch
Description: 13.5 g/day
Study NCT01992783 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: 13.5 g/day
Study NCT02988583 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgery using low viscosity silicone oil
Description: Pars plans vitrectomy using low viscosity silicone oil
Study NCT02988583 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery using high viscosity silicone oil
Description: Pars plans vitrectomy using high viscosity silicone oil
Study NCT02188316 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Jumbo forceps
Description: comparison of different polypectomy devices
Study NCT02188316 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hot biopsy forceps
Description: comparison of different polypectomy devices
Study NCT00705939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taliglucerase alfa
Description: Intravenous infusion every 2 weeks
Study NCT01241214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-129968
Description: ACT-129968 (Dose 1, Dose 2, or Dose 3) or matching placebo administered orally twice daily
Study NCT01241214 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ACT-129968
Description: ACT-129968 (Dose 1, Dose 2, or Dose 3) or matching placebo administered orally twice daily
Study NCT01241214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-129968
Description: ACT-129968 (Dose 4) \& matching placebo administered orally once daily
Study NCT01241214 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ACT-129968
Description: ACT-129968 (Dose 4) \& matching placebo administered orally once daily
Study NCT01241214 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cetirizine
Description: Ceterizine administered once daily
Study NCT01241214 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cetirizine
Description: Ceterizine administered once daily
Study NCT01241214 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo administered twice daily.
Study NCT04429620 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Immunfluorescence
Description: Serum indirect immunofluorescent (IIF) method is used, analysis is performed under an automated microscope.
Study NCT01503255 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behavioral group therapy
Description: 6 weekly 90-minute group sessions
Study NCT01503255 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: health education group
Description: 6 weekly 90-minute group sessions
Study NCT05055193 — intervention group
Intervention type: DRUG
Intervention: Evaluation at 24 months corrected age: respiratory outcome, Neurodevelopmental outcome, Growth outcome
Description: Data concerning the 24 months corrected age outcomes were collected from the medical records of the ECL'AUR preterm infants follow-up network.
Study NCT02825095 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Talc Pleurodesis
Description: chest tube type PIGTAIL 10 - 14 Fr will be inserted to the pleural space. In case of fluid discharges less than 250 cc/24, talc pleurodesis will be performed
Study NCT02825095 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Indwelling Pleural Catheter
Description: Indwelling Pleural Catheter type PLEURAX will be inserted to the pleural space. the patients will be discharged with the pleural catheter.
Study NCT02825095 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: chest ultrasound
Description: All insertion of a chest drain will be guided by ultrasound
Study NCT02825095 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Local anesthesia
Description: Inserting a chest drain will be after local anesthesia with 10-20 mL of Lidocaine hydrochloride 20MG/ML - Esracain injection 2%
Study NCT02825095 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chest Tube
Description: chest tube type PIGTAIL 10 - 14 Fr will be inserted to the pleural space. In case of fluid discharges less than 250 cc/24, talc pleurodesis will be performed
Study NCT00909311 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-450
Description: capsules, QD, 1 dose in each cross-over period
Study NCT00909311 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ritonavir
Description: capsule, QD, 1 dose in each cross-over period
Study NCT00328770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus given intravenously or orally to achieve target levels of 12-20ug/l
Study NCT02741102 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Uterine Transplant
Description: Treating Absolute Uterine Factor Infertility by Uterus Transplant. Potential recipients undergo IVF to obtain 6 embryos for cryopreservation followed by live donor uterine transplant. After 1 year, embryo transfer is done to achieve pregnancy. Delivery is by Caesarian section. The recipient may have up to 2 children by these methods and then the uterus is removed so that immunosuppression can be stopped.
Study NCT02467933 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo letter
Description: The placebo letter describes a new rule in Medicare that requires prescribers to enroll in Medicare
Study NCT02467933 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Initial Informative letter
Description: The intervention is a letter that describes the Seroquel prescribing activity of the individual in comparison to a peer group of similar prescribers. It highlights the fact that the prescriber's activity is highly unlike her peers.
Study NCT02467933 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Followup Informative Letter
Description: The followup informative letter is identical to the initial informative letter except it provides an update on more recent prescribing rather than a description of earlier prescribing.
Study NCT03239717 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Whey protein powder
Description: Participants in the Control Arm will replace two-thirds of participants dietary protein intake with a commercially available whey protein powder.
Study NCT03239717 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BCAD2
Description: Participants in the Experimental Arm will replace two-thirds of participants dietary protein intake with BCAD2 (Mead Johnson), a BCAA-free medical food.
Study NCT01571583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: Type=exact number, unit=mg, number=375, form=tablet, route=oral. Patients will receive 2 oral tablets (750 mg) every 8 hours for 12 weeks.
Study NCT01571583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2a
Description: Type=exact number, unit=µg, number=180, form=injection, route=subcutaneous. 180 microgram (µg) per week, subcutaneous injection, for 48 weeks.
Study NCT01571583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Type=exact number, unit=mg, number=200, form=tablet, route=oral. Starting from 600 mg (3 tablets) per day on Day 1. This dose will become higher or lower based on blood results and the investigators opinion (to a goal of 1000 to 1200 mg/day \[5 to 6 tablets\] based on subject weight), twice daily regimen, for 48 weeks.
Study NCT04561154 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire
Description: three months after hospitalization, a questionnaire will be sent to patients. If necessary, patient will be seen in consultation of geriatry, otorhinolaryngology, pneumology, neuropsychology
Study NCT04830670 — intervention group
Intervention type: PROCEDURE
Intervention: sinus floor elevation with lateral approach
Description: sinus floor elevation with lateral approach. 6 months healing phase. implant site preparation with trephine bur and bone specimen retrieval.
Study NCT02433600 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cow's milk-based infant formula
Study NCT02433600 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cow milk-based infant formula with enriched protein fractions
Study NCT03865693 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: scarmbler therapy
Description: Scrambler therapy is a patient-specific electrocutaneous nerve stimulation device.
Study NCT03865693 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: scarmbler therapy
Description: Scrambler therapy is a patient-specific electrocutaneous nerve stimulation device.
Study NCT00291447 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ch806
Description: ch806 is a chimeric (part human, part mouse) antibody which recognizes and attaches to a protein called the 806 antigen (a type of EGFR), which is found on the surface of some cancer cells.
Study NCT00453271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NB-002
Study NCT00453271 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Vehicle control
Study NCT02488395 — intervention group
Intervention type: OTHER
Intervention: fMRI
Description: The investigators will use a non invasive fMRI technique centred on the superior colliculus during the presentation of flickered check-boards with varying contrast (1, 3, 5 and 9 %).
Study NCT02488395 — intervention group
Intervention type: OTHER
Intervention: Ophthalmologic evaluation
Description: The aim of this experiment is the evaluate the functional state of a visual structure. Therefore, with this ophthalmologic test, the investigators will control if the participant does not present major visual deficits. This examination will evaluate the visual acuity and the visual field. A funduscopic examination will also be performed to check the retina.
Study NCT02488395 — intervention group
Intervention type: OTHER
Intervention: visual psychophysics test
Description: This test will allow to control the sensitivity of the participant to our contrast. The participant will be asked to look at screen on which three static check-boards will be presented. The participant will have to choose the two check-boards with the closest contrast.
Study NCT03473431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: single infusion of 0.5 mg / kg ketamine
Study NCT03473431 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: control
Description: physiological solution at 0.9 % with the same physical characteristics of ketamine solution,
Study NCT04293770 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Indirect adhesive restoration of posterior teeth
Description: Indirect restoration of significant loss of dental hard tissue
Study NCT01246791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPC-01
Description: NPC-01, contains 1mg norethisterone and 0.02mg ethinyl estradiol will be administered orally under the fasting condition
Study NCT03936374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986205
Description: Participants will receive BMS-986205 on Days 1 and 15
Study NCT03936374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omeprazole
Description: Participants will receive omeprazole on Days 10 to 15
Study NCT05892809 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: use an incubator cover
Description: Vital signs of term and preterm newborns were measured separately and with and without an incubator cover.
Study NCT01793415 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IodoCarb (r)
Description: Powder, 3 grams daily for 28+-2 days
Study NCT01793415 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Non-iodinated activated charcoal 3 g daily for 28+-2 days
Study NCT02407678 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: AAV-mediated REP1 gene replacement
Description: AAV vector carrying human REP1 gene is delivered into the treated eye by subretinal injection
Study NCT02597621 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT01521273 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bean varieties
Description: 10 x 50 g/ arm
Study NCT04453579 — intervention group
Intervention type: BEHAVIORAL
Intervention: Telephonic interview during the Italian lockdown.
Description: The interview was composed of socio-demographic items lockdown, and dichotomous questions about physical and mental health in relation to the COVID-19 emergency
Study NCT02020486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel
Description: 2 mg up to 4 mg
Study NCT02020486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel
Description: 2 mg up to 6 mg
Study NCT01747057 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dynamic-parameters-guided fluid management
Description: ● In preload-responsive patients defined by the following dynamic parameters: Patients fully adapted to mechanical ventilation\* and with sinus rhythm.~1. PPV >12%. PPV: Pulse pressure variation PPV = (PPmax-PPmin)/ \[(PPmax+PPmin)/2\] x100 (during 5 respiratory cycles)~2. SVV > 12% (15). SVV: Stroke volume variation~   * A tidal volume (Vt) ≥ 7-10cc/kg in mechanically ventilated (in a controlled mode - control volume or control pressure) and well-adapted patients without any inspiratory effort should be guaranteed.~Fluid loading must be performed with crystalloids (1omL/Kg) or colloids (5ml/Kg) every 30 minutes until PPV-SVV \< 12%, while hypoperfusion signs are present. Continue resuscitation following Surviving Sepsis Campaign rules excluding more fluid administration (as described in the standard intervention once CVP>12).~● Non-preload responsive patients (defined as PPV or SVV \< 12%) will resume the same protocol as responders when fluid response parameters are negative.
Study NCT01747057 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard-guided-fluid management
Description: Fluid loading in patients with hypotension or elevated lactates until normalization of MAP (> 65mmHg) or CVP > 12mmHg. If CVP reaches > 12 mmHg and MAP remains \< 65mmHg, norepinephrine should be started to reach MAP > 65mmHg. Once MAP is restored, if hypoperfusion signs persist (elevated lactate or urine output \< 0.5mL/Kg/h), ScvO2/SvO2 must be measured. In order to reach a ScvO2 ≥70% or SVO2 ≥65%, consider giving blood transfusion if hemoglobin level (Hb) ≤ 7g/dL, and also consider dobutamine (initial dose 2,5 µg/kg/min, increased by 2,5 µg/kg/min every 30 min up to a maximum dose of 20 µg/kg/min, presence of arrhythmia, or FC>110bpm). At that point, if hypoperfusion signs remain present, consider restart protocol from the beginning.
Study NCT01726946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-135
Description: 12 weeks of VX-135
Study NCT01726946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: 12 weeks of ribavirin
Study NCT03650998 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: See arm description
Study NCT03650998 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: See arm description
Study NCT04067947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XG005
Description: XG005 Tablet
Study NCT04067947 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo Tablet
Study NCT02064387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2857916
Description: A clear or opalescent solution for IV infusion with unit dose strength of 20 mg/mililiter (mL) for multiple dose levels.
Study NCT03553823 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin biopsies
Description: At Baseline, two 6-mm punch biopsies were taken, one from the identified active plaque (TCS ≥ 6) and one from never-lesional skin. At the End-of-study Visit, one biopsy was taken from the same area of the active plaque sampled at Baseline.
Study NCT03097900 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine Citrate
Description: 25 patients after elective colorectal surgery will be given 100 mg caffeine citrate orally diluted in 50 ml apple flavored water three times per day starting on the morning of postoperative day 1 after surgery until flatus will occur for the first time or to a maximal period time of 7 days, whichever comes earlier.
Study NCT03097900 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: 25 patients after elective colorectal surgery will be given 50 ml apple flavored water three times per day starting on the morning of postoperative day 1 after surgery until flatus will occur for the first time or to a maximal period time of 7 days, whichever comes earlier.
Study NCT04568408 — intervention group
Intervention type: DEVICE
Intervention: Xiaomi MiBand 5
Description: Comparison of sleep-monitoring device against polysomnography (PSG)
Study NCT00794560 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: patient education
Description: Possible, individualized interventions:~* Improvement of patient's knowledge about medication, therapy and drug application by providing detailed written information material~* Providing a complete equipment package for self-injection (disinfection patches, patches, plasters, waste disposal box for used syringes)~* Patient training: oral instructions for self-injection (and application, if required), exercising the injection technique on a phantom~* First self-injection under control of a specially trained pharmacist
Study NCT01665963 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TopClosure(c) System
Study NCT01665963 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pressure Bandage
Study NCT03161756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Denosumab is a fully human monoclonal immunoglobulin type 2 (IgG2) antibody that binds with high affinity and specificity to RANK ligand (RANKL) and neutralises the activity of human RANKL, similar to the action of endogenous osteoprotegerin (OPG). Denosumab binding prevents the activation of RANK and inhibits the formation, activation, and survival of osteoclasts. As a consequence, bone resorption and cancer-induced bone destruction are reduced.
Study NCT03161756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a human monoclonal antibody that targets the programmed death-1 (PD-1) cluster of differentiation 279 (CD279) cell surface membrane receptor. Nivolumab inhibits the interaction of PD-1 with its ligands, PD-L1 and PD-L2, resulting in enhanced T-cell proliferation and interferon-gamma (IFN-γ) release in vitro.
Study NCT03161756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab is a fully human monoclonal immunoglobulin specific for human cytotoxic T-lymphocyte antigen 4 (CTLA-4), which is expressed on a subset of activated T cells. Ipilimumab is a monoclonal antibody(mAb) that binds to CTLA-4 and blocks the interaction of CTLA-4 with its ligands, cluster of differentiation antigen 80 / cluster of differentiation antigen 86 (CD80 / CD86). Blockade of CTLA-4 has been shown to augment T-cell activation and proliferation, including the activation and proliferation of tumor-infiltrating T-effector cells.
Study NCT03413930 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transanal total mesorectal excision
Description: Patients undergo transanal total mesorectal excision.（assisted by laparoscopy to control the IMA）
Study NCT03413930 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic total mesorectal excision
Description: Patients undergo Laparoscopic total mesorectal excision.
Study NCT02239263 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nucleus 6 Sound Processor
Study NCT03453983 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcrainial Direct Current Stimulation (tDCS)
Description: Transcranial direct current stimulation (tDCS) is a safe non-invasive form of brain stimulation, which modulates, through the application of weak direct current, cortical excitability. The applied subthreshold current passes through two externally placed electrodes, an anode and cathode.
Study NCT03453983 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcrainial Direct Current Stimulation (tDCS)
Description: Transcranial direct current stimulation (tDCS) is a safe non-invasive form of brain stimulation, which modulates, through the application of weak direct current, cortical excitability. The applied subthreshold current passes through two externally placed electrodes, an anode and cathode.
Study NCT02474082 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: Secukinumab 150 mg, 1 ml liquid formulation in a pre-filled pen for s.c. injection